| Pick of the Month Last month, in a new exciting CRISPR first, scientists developed what could become a one-time CRISPR-Cas9 treatment for Angelman syndrome that would replace frequent, invasive injections. We interviewed neurobiologist Mark Zylka, who led the study, and Dr Arthur Beaudet, a paediatrician and molecular geneticist not involved in the study, to hear what this means for current and future patients. If you missed the story, you have another chance to catch it here. | |
